Dennis Plenker

List of Publications by Year
in descending order

22 papers	1,921 citations	567281 15 h-index	713466 21 g-index
24 all docs	24 docs citations	24 times ranked	3841 citing authors

#	Article	IF	Citations
1	Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics. Cancer Research, 2022, 82, 1174-1192.	0.9	21
2	Lead identification using 3D models of pancreatic cancer. SLAS Discovery, 2022, 27, 159-166.	2.7	17
3	CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. Molecular Cancer Therapeutics, 2022, 21, 821-830.	4.1	4
4	Single-Pass vs 2-Pass Endoscopic Ultrasound-Guided Fine-NeedleÂBiopsy Sample Collection for Creation ofÂPancreatic Adenocarcinoma Organoids. Clinical Gastroenterology and Hepatology, 2021, 19, 845-847.	4.4	18
5	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	1.3	90
6	Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Clinical Cancer Research, 2021, 27, 226-236.	7.0	15
7	Advances in preclinical evaluation of experimental antibody-drug conjugates. , 2021, 4, 745-754.		3
8	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nature Communications, 2021, 12, 5505.	12.8	30
9	Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Cancer Discovery, 2020, 10, 1566-1589.	9.4	90
10	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Annals of Surgery, 2020, 272, 427-435.	4.2	61
11	Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 541-552.	3.3	14
12	Organoid models for translational pancreatic cancer research. Current Opinion in Genetics and Development, 2019, 54, 7-11.	3.3	57
13	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	17
14	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clinical Cancer Research, 2018, 24, 1337-1343.	7.0	71
15	Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. JCO Precision Oncology, 2018, 2, 1-6.	3.0	2
16	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	12.8	107
17	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	9.4	676
18	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Science Translational Medicine, 2017, 9, .	12.4	55

#	Article	IF	Citations
19	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clinical Cancer Research, 2016, 22, 4837-4847.	7.0	223
20	Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget, 2015, 6, 38458-38468.	1.8	19
21	Cell-Autonomous and Nonâ€“Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer. Cancer Discovery, 2014, 4, 246-257.	9.4	93
22	CD74â€“NRG1 Fusions in Lung Adenocarcinoma. Cancer Discovery, 2014, 4, 415-422.	9.4	238